Zobrazeno 1 - 10 of 13 pro vyhledávání: '"D B, Muchmore"'
1
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
Autor: T. J. Powles, S. Eckert, K. A. Krueger, Alberto Costa, Avraham Karasik, Jane A. Cauley, Virgil Craig Jordan, Kong Wah Ng, Marc E. Lippman, S. L. Silfen, D. W. Purdie, E. L. Walls, Jan J. Stepan, J. Farrerons, Monica Morrow, Larry Norton, H. Schmitt, D. Mellstrom, D. B. Muchmore
Publikováno v: Breast Cancer Research and Treatment. 65:125-134
Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0135c8293e9d3f13c3d10afbc96721cc
https://doi.org/10.1023/a:1006478317173
Zobrazit plný text záznamu
2
Self-monitoring of blood glucose in overweight type 2 diabetic patients
Autor: M. Miller, J. Springer, D. B. Muchmore
Publikováno v: Acta Diabetologica. 31:215-219
Self-monitoring of blood glucose (SBGM) is widely recommended for both type 1 and type 2 diabetic patients despite the lack of evidence of benefit in glucose control or as an aid in weight loss in type 2 subjects. This study tested the hypothesis tha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb148268f4ce3ccd6001d499e89b90c7
https://doi.org/10.1007/bf00571954
Zobrazit plný text záznamu
3
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients
Autor: M, Dowsett, N J, Bundred, A, Decensi, R C, Sainsbury, Y, Lu, M J, Hills, F J, Cohen, P, Veronesi, M E, O'Brien, T, Scott, D B, Muchmore
Publikováno v: Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 10(9)
Raloxifene is a selective estrogen receptor (ER) modulator approved for prevention and treatment of postmenopausal osteoporosis. This is an exploratory study of raloxifene in primary breast cancer patients.Postmenopausal women (50-80 years of age), w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c48aeb5484097e855d2ddc18277bbb65
https://pubmed.ncbi.nlm.nih.gov/11535548
Zobrazit plný text záznamu
4
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation
Autor: J A, Cauley, L, Norton, M E, Lippman, S, Eckert, K A, Krueger, D W, Purdie, J, Farrerons, A, Karasik, D, Mellstrom, K W, Ng, J J, Stepan, T J, Powles, M, Morrow, A, Costa, S L, Silfen, E L, Walls, H, Schmitt, D B, Muchmore, V C, Jordan, L G, Ste-Marie
Publikováno v: Breast cancer research and treatment. 65(2)
Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f06300a512e6d7181114f068d1f263ad
https://pubmed.ncbi.nlm.nih.gov/11261828
Zobrazit plný text záznamu
5
A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
Autor: K M, Prestwood, M, Gunness, D B, Muchmore, Y, Lu, M, Wong, L G, Raisz
Publikováno v: The Journal of clinical endocrinology and metabolism. 85(6)
Raloxifene HCl, a selective estrogen receptor modulator, has been shown to increase bone mineral density (BMD) and decrease biochemical markers of bone turnover in postmenopausal women without stimulatory effects on the breast and uterus. However, it
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fe563c474ca349db1d6b39b96d4006bb
https://pubmed.ncbi.nlm.nih.gov/10852452
Zobrazit plný text záznamu
6
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group
Autor: J, Rosenstock, E, Samols, D B, Muchmore, J, Schneider
Publikováno v: Diabetes care. 19(11)
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM.Of the previously treated NIDDM patients, 416 entered this multicenter rand
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c96285ccb37d419079d79ce22254cb66
https://pubmed.ncbi.nlm.nih.gov/8908379
Zobrazit plný text záznamu
10
Glycogen synthesis stimulation by adenylate cyclase inhibition in rat epididymal adipocytes
Autor: C de Haën, B. U. Raess, D B Muchmore
Publikováno v: Biochemistry. 22:2214-2221
The effects of adenylate cyclase inhibition on the transport of glucose and fructose and their incorporation into glycogen were investigated in order to assess the extent to which lowered cAMP levels can take part in the various components of glycoge
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b04120f79760a5dfbc8f990b07b4209
https://doi.org/10.1021/bi00278a024
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje